Anti-epileptic Drugs Market Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
 |
| Anti-epileptic Drugs Market |
Patients who have seizures are
given anti-epileptic medications. The most common sign of epilepsy is frequent
seizures, which are brief bursts of electrical activity in the brain that
momentarily impair brain function. Some seizures produce jerking and shaking of
the body, while others create difficulties such as loss of awareness or odd
sensations. Anti-epileptic drugs (AEDs) are a broad category of medications
that are increasingly being utilised for disorders other than epilepsy, such as
migraine prevention, neuropathic pain, and bipolar disorder. Anti-epileptic
medications are classified into three generations. Each generation represents a
distinct specification.
The increasing number of
collaborations by leading Anti-epileptic
Drugs Market competitors
is one of the major factors boosting market expansion throughout the predicted
period. For example, in May 2021, the Epilepsy Foundation, a non-profit
national foundation based in the United States, announced a collaboration with
Eisai Inc., a Japanese pharmaceutical company, to create the Epilepsy Digital
Experience Navigator (EDEN), a platform designed to empower people with
epilepsy, caregivers, and clinicians to use data to better understand and
improve the epilepsy journey.
Furthermore, industry
participants are concentrating on obtaining regulatory clearances, which is
likely to fuel the growth of the worldwide
anti-epileptic drugs market. For example, in July 2019, Pfizer, Inc.
announced that the US Food and Drug Administration has approved the first
generics of Lyrica (pregabalin) as an additional medication for the treatment
of partial-onset seizures in patients aged 17 and older.
Comments
Post a Comment